Cereno Scientific: Clinical-stage orphan opportunity - Redeye

Redeye initiates coverage of Cereno Scientific, a biotech company developing drugs to treat both rare and common cardiovascular diseases. Cereno is about to initiate a phase II clinical trial with lead candidate CS1 in pulmonary arterial hypertension, a commercially attractive orphan disease.

Länk till analysen i sin helhet: https://www.redeye.se/research/819212/cereno-scientific-clinical-stage-orphan-opportunity?utm_source=finwire&utm_medium=RSS